## 2-(4-Chlorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxylic acid: An intriguing compound with potential
**2-(4-Chlorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxylic acid** is a complex organic compound with a rather long and unwieldy name. Let's break it down:
* **2-(4-Chlorophenyl)sulfonyl:** This part describes a sulfonyl group (SO2) attached to a phenyl ring with a chlorine atom at the 4th position.
* **3,4-dihydro-1H-isoquinoline-3-carboxylic acid:** This describes a modified isoquinoline ring system. Dihydro indicates two hydrogen atoms have been added, and the 3-carboxylic acid specifies a carboxyl group (COOH) attached to the 3rd position.
**Why is this compound important for research?**
This compound is not widely known, and there's limited information about its specific applications. However, its structure hints at some possible research areas:
* **Pharmacology:** The presence of a sulfonyl group and a modified isoquinoline ring suggests potential pharmacological activity. Isoquinoline derivatives are known to exhibit various biological activities, including anti-inflammatory, anti-cancer, and antimicrobial properties. The sulfonyl group can contribute to binding interactions with proteins, further enhancing potential therapeutic applications.
* **Organic chemistry:** The compound serves as a synthetic target for developing new synthetic methodologies and exploring the chemistry of sulfonyl-containing heterocycles. It can be used as a building block for creating more complex and diverse molecules with potential applications in various fields.
* **Materials science:** The compound's unique structure could potentially lead to novel materials with interesting properties. For example, the sulfonyl group could contribute to increased stability or promote specific interactions with other molecules.
**To further explore the significance of this compound, more information is needed:**
* **Specific research objectives:** What are the researchers aiming to achieve by studying this compound?
* **Biological activity:** Does it exhibit any specific biological activity, like inhibiting enzymes or interacting with specific receptors?
* **Synthesis and characterization:** How is it synthesized and what are its physical and chemical properties?
**In summary, while the specific importance of 2-(4-chlorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxylic acid is not readily available, its structure suggests potential for research in pharmacology, organic chemistry, and materials science. Further research is required to fully understand its significance and potential applications.**
ID Source | ID |
---|---|
PubMed CID | 4205458 |
CHEMBL ID | 1303972 |
CHEBI ID | 119831 |
Synonym |
---|
MLS000760836 |
smr000370941 |
2-(4-chlorophenyl)sulfonyl-3,4-dihydro-1h-isoquinoline-3-carboxylic acid |
CHEBI:119831 |
AKOS000121710 |
HMS2654G23 |
2-(4-chloro-benzenesulfonyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid |
CHEMBL1303972 |
2-(4-chlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid |
1008997-24-7 |
EN300-00701 |
Q27207310 |
Z45557478 |
CS-0218373 |
2-(4-chlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylicacid |
Class | Description |
---|---|
isoquinolines | A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
DNA polymerase beta | Homo sapiens (human) | Potency | 39.8107 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
geminin | Homo sapiens (human) | Potency | 10.3225 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |